Biocon Corporate Presentation

Annual Financial Highlights FY 21 FY20 Revenue +13% 7,360Cr *6,462Cr Core EBITDA¹ +15% 2,430Cr *2,108Cr % margin 33% 33% EBITDA +8% 1,907Cr *1,765Cr % margin 26% 27% Profit Before Tax² (11) % 1,077Cr *1,215Cr % margin 15% 19% Net Profit # (4)% *754Cr *789Cr % margin 5% 9% 1 Core EBITDA defined as EBITDA before R&D, forex and licensing income; 2 from continued operations Biocon Biosimilars +21% | Research Services +9% | Generics +6% Forex loss of 9Cr in FY21 vs *65Cr of Forex gain in FY20 Gross R&D spends at *627Cr in FY21 (13% of ex-Syngene revenues) R&D spends in P&L #533Cr for FY21 Excluding Bicara Fair Valuation gain of 160 Cr: Core EBITDA 32%, dn 1% EBITDA *1,747Cr at 24% Net profit at *594Cr 19

View entire presentation